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Glial cell line-Derived Neurotrophic Factor (GDNF) binds the GFRα1 receptor, and 
the GDNF–GFRα1 complex binds to and activates the transmembrane RET tyrosine 
kinase to signal through intracellular Akt/Erk pathways. To dissect the GDNF–GFRα1–
RET signaling complex, agents that bind and activate RET directly and independently of 
GFRα1 expression are valuable tools. In a focused naphthalenesulfonic acid library 
from the NCI database, we identified small molecules that are genuine ligands binding 
to the RET extracellular domain. These ligands activate RET tyrosine kinase and afford 
trophic signals irrespective of GFRα1 co-expression. However, RET activation by these 
ligands is constrained by GFRα1, likely via an allosteric mechanism that can be 
overcome by increasing RET ligand concentration. In a mouse model of retinitis 
pigmentosa, monotherapy with a small molecule RET agonist activates survival signals 






A genuine ligand of RET receptor ectodomain was identified, which acts as an agonist. 
Binding and agonism are independent of a co-receptor GFRα which is required by the 
natural growth factor GDNF, and are selective for cells expressing RET. The lead agent 
protects neurons from death in vivo. This work validates RET receptor as a druggable 
therapeutic target, and provides for potential leads to evaluate in neurodegenerative 
states. We also report problems that arise when screening chemical libraries.  
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Introduction 
Glial cell line-derived neurotrophic factor (Nutt, Burchiel et al.), a distant member of 
the TGF-beta superfamily, mediates pro-survival signaling in neuronal populations 
(Airaksinen and Saarma 2002, Runeberg-Roos and Saarma 2007, Ibanez 2013). 
Indeed, GDNF has been tested in animal models of neurodegeneration, notably 
Parkinson’s Disease (PD) , Amyotrophic Lateral Sclerosis, neuropathic pain (Boucher, 
Okuse et al. 2000), and eye diseases such as retinitis pigmentosa (RP) and glaucoma 
(McGee Sanftner, Abel et al. 2001, Gregory-Evans, Chang et al. 2009, Ohnaka, Miki et 
al. 2012). 
In human clinical trials for PD, the therapeutic efficacy of GDNF and related factor 
neurturin has been controversial, with post hoc analysis showing clinically significant 
motor improvement (Josephy-Hernandez, Jmaeff et al. 2017, Whone, Luz et al. 2019). 
In part, GDNF therapy remains a challenging strategy due to the limited understanding 
of the physiology of its receptors, varying receptor/co-receptor expression patterns, and 
binding or functional interactions with other factors or matrix proteins in vivo (Sariola 
and Saarma 2003, Gash, Zhang et al. 2005, Touchard, Heiduschka et al. 2012). GDNF 
can bind to extracellular matrix and transmembrane heparan sulfate proteoglycans and 
neuronal cell adhesion molecules NCAM (Hamilton, Morrison et al. 2001, Bespalov and 
Saarma 2007), affecting its bioavailability (Salvatore, Ai et al. 2006). These issues could 
be solved using RET agonists that are not bound/trapped, and which may exhibit more 
favorable kinetics and avoid the need for invasive delivery methods. 
GDNF binds first to the GPI-anchored GDNF Family Receptor alpha 1 (GFRα1) 
receptor, and the resulting GDNF/GFRα1 complex then activates the RET receptor 
tyrosine kinase (RTK). There appears to be a functional cross-regulation between RET 
and GFRα1, as reported for another receptor family, the neurotrophin receptors 
(Ivanisevic, Banerjee et al. 2003). However, the required concomitant presence of 
GFRα1 and RET receptors to activate measurable GDNF-induced signals limits 
biological and pharmacological studies.  
For example, studies of cross-regulation are difficult, and access to receptor-specific 
ligands would be useful to probe this question. Moreover, the pharmacological utility of 
GDNF may be limited to indications where both receptors are present in the same 
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tissue in disease. However, there are indications where RET is expressed without 
GFRα1, for example, in the retina (Brantley, Jain et al. 2008). Selective, small molecule 
RET agonists may provide a broader range of tissue targets and activities. 
Here we report chemical biology studies to develop small molecules that selectively 
activate RET-pY1062, which activates Akt and Erk pathways leading to cell survival-
promoting signals. Activity is dependent on RET-expression, but independent of 
GFRα1-expression. We used these small molecules as tools to demonstrate regulation 
of RET by GFRα1, a process which is likely allosteric. A RET agonist, compound 8, was 
used as a therapeutic lead in an animal model of retinitis pigmentosa, to validate the 
RET receptor as a druggable target in this disease. 
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Materials and Methods 
Cell Lines 
MG87 RET are murine MG87 fibroblasts stably transfected with RET proto-
oncogene cDNA (Eketjall, Fainzilber et al. 1999), and were cultured in DMEM 
containing 10% FBS, 2 mM L-Glutamine, 10 mM HEPES, 100 U/ml 
Penicillin/Streptomycin, and 2 μg/ml puromycin.  MG87 RET cells were transfected with 
a GFRα1 cDNA construct containing Blasticidin resistance gene to generate the MG87 
RET/GFRα1 cell line, and were cultured in the same media with the addition of 5 μg/ml 
Blasticidin S. MG87 TrkA cells were transfected with human NGF receptor TrkA cDNA, 
and cultured in DMEM 10% FBS supplemented with 250 μg/ml G418. 
MG87RET/GFRα1 cell lines were stably transfected with PathDetect Elk-1 system 
(Stratagene) harboring Luciferase reporter under the control of Erk activity. Cells were 
cultured in DMEM, 10% FBS, 15 mM HEPES pH 7.2, 100 μg/ml normocin (Invivogen), 2 
μg/ml puromycin, 500 μg/ml (Sidorova, Matlik et al. 2010). Growth factors GDNF and 
NGF were purchased from Peprotech (catalogue 450-10, 450-01) and FGF2 from 
Sigma Aldrich (catalogue F0291).  Cell lines were routinely tested and verified to be free 
of mycoplasma (Venor GeM Mycoplasma Detection Kit). 
 
Luciferase assay 
Initial screening of a chemical library was performed in MG87RET/GFRα1 cells with 
luciferase reporter controlled by Erk (Sidorova, Matlik et al. 2010).  20000 cells per well 
were plated in 96-well plates in DMEM, 10% FBS, 15 mM HEPES pH 7.2, 100 μg/ml 
normocin, 1% DMSO and incubated overnight under standard conditions. Cells were 
treated with tested compounds dissolved in DMEM, 15 mM HEPES pH 7.2, 1% DMSO 
to achieve final concentration of 5 and 20 μM for 24-30 hr. Afterwards, cells were lysed 
with 25 μl of cell lysis buffer (Promega) per well and frozen and thawed once. Five μl of 
lysate was combined with 20 μl of luciferase assay reagent (Promega) on ice.  
Luminescence was measured using MicroBeta 2 instrument (PerkinElmer) twice. 
Results of the second run were used for analysis.  
 
RET phosphorylation assays 
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Phosphorylation of RET was assessed as previously described (Leppanen, Bespalov et 
al. 2004). MG87 RET cells were plated on 35 mm tissue culture dishes, left to attach to 
the surface overnight and then transfected with 4 μg/dish of GFRα1-expressing plasmid 
using Lipofectamine 2000 (Invitrogen) for DNA delivery as described by manufacturer. 
Next day cells were starved for 4 hr in serum-free DMEM containing 15 mM HEPES, pH 
7.2 and 1% DMSO and stimulated with 5-100 μM compounds or GDNF (200 ng/ml) for 
15 min diluted in serum-free DMEM containing 15 mM HEPES, pH 7.2 and 1% DMSO. 
Afterwards, cells were washed once with ice-cold PBS containing 1 mM Na3VO4 and 
lysed on ice in 0.5 ml per well of RIPA-modified buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% NP-40, 1% triton-X100, 10% glycerol, EDTA-free 
EASYpack, protease inhibitor cocktail (Roche), 1 mM Na3VO4, 2.5 mg/ml of sodium 
deoxycholate). Plates were incubated on horizontal shakers for 30 min with vigorous 
shaking, lysates were collected in Eppendorf tubes and centrifuged in a microfuge for 
10 min at 6000g at 4°C to precipitate cell debris. Supernatants were incubated overnight 
with 2 μg/ml of anti-RET C-20 antibodies (Santa-Cruz Biotechnology, Inc., sc-1290) and 
protein G-conjugated beads (Thermo Fisher Scientific, Cat # 10004D). Beads were 
washed 3 times with 1x TBS (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) with 1% triton X-
100, bound proteins were eluted by 50 μl of 2x Laemmli loading buffer, resolved on 
7.5% SDS-PAGE and then transferred to a nitrocellulose membrane. Total 
phosphorylated residues were then probed using the 4G10 antibody (1:1,000, Millipore, 
Cat # 05-321) followed by anti-mouse antibodies conjugated with horse radish 
peroxidase (1 : 1,500, DAKO, Cat# P0447) in TBS-T containing 3% skimmed milk. To 
confirm equal loading, membranes were stripped, washed, blocked, and re-probed with 
anti-RET C-20 antibodies (1:500, Santa-Cruz Biotechnology, Inc.) followed by anti-goat 
antibodies conjugated with horse radish peroxidase  (1:1,500, DAKO, Cat# P0449) in 
TBS-T containing 3% skimmed milk. Stained bands were visualized with ECL or 
femptoECL reagent (Pierce) using LAS-3000 imaging system (Fuji). 
 
Surface Plasmon Resonance (SPR) 
Binding interactions between the small molecules (4 mM stocks of compounds 8 and 
9 in 5% (v/v) DMSO) and human RET protein (R&D Systems #1168-CR/CF) were 
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examined at 25°C using a BIACORE T200 system (GE Healthcare Bio-Sciences AB, 
Upsala, Sweden; Control software v2.0 and Evaluation software v1.0). Protein-grade 
Tween 20 and Empigen detergents (Anatrace #APT020 and #D350, respectively), 
anhydrous DMSO (Sigma #276855), Pierce Gentle Ag/Ab Elution buffer (Thermo Fisher 
#21027) and all other chemicals were reagent grade quality. The carrier-free proteins 
were immobilized to S-series CM5 sensors (10 µg/ml RET in 10 mM sodium acetate pH 
5.5) using the Biacore Amine Coupling Kit as recommended by the manufacturer (1500 
– 5000 RU final density) in PBS-T running buffer (10 mM phosphate, pH 7.4; 150 mM 
NaCl; 0.05% (v/v) Tween-20). Corresponding reference surfaces were prepared in the 
absence of protein. The immobilized surfaces were active as confirmed by binding of 
specific anti-Ret monoclonal antibodies (0.25 mg/ml stock, Abcam ab134100) in dose-
dependent binding. Between titration series, the surfaces were regenerated at 50 μl/min 
using two 30 sec pulses of solutions I (0.1% (v/v) Empigen in Pierce Gentle Elution 
buffer), II (1.0 M NaCl and 0.1% (v/v) Empigen in 50 mM HCl), and III (1.0 M NaCl and 
0.1% (v/v) Empigen in 50 mM NaOH). 
Using PBS-T containing 5% (v/v) DMSO, fixed 100 µM concentrations of compound 
9 (negative) and compound 8 (positive) were injected in-tandem over reference and 
protein-immobilized surfaces at 25 μl/min (60 sec association, 60-180 sec dissociation) 
to establish binding specificity. To examine binding kinetics and affinity, compound 8 
was titrated in single-cycle (25 μl/min x 1 sec association + 60-600 sec dissociation) and 
multi-cycle (10 μl/min x 10 min association + 20 min dissociation) mode. Between 
titration series, the surfaces were regenerated at 50 μl/min using two 30 sec pulses of 
solutions I (1.0 M NaCl and 0.1% (v/v) Empigen in PBST-DMSO), II (1.0 M NaCl and 
0.1% (v/v) Empigen in 50 mM NaOH), and III (50 mM NaOH). 
 
Biochemical Assays 
For biochemical assays, cells were seeded onto 6-well plates (0.4 x 106 cells/well) 
and cultured overnight. Cells were serum-starved for 2 hr and then stimulated with 
compounds for 20 minutes before preparation of cell lysates in 100 μl lysis buffer (20 
mM Tris-HCl pH 7.5, 137 mM NaCl, 2 mM EDTA, 1% Nonidet P-40) containing a 
protease inhibitor cocktail. Lysates were centrifuged at 4°C for 10 minutes at 6000g, 
This article has not been copyedited and formatted. The final version may differ from this version.














MOL # 118950 
 9 
prior to protein quantification using the Bradford assay (BioRad). After SDS-PAGE, 
Western transfer to PVDF membranes, and blocking steps, an overnight incubation at 
4°C with the primary antibodies pAkt, pErk, total Akt, total Erk (Cell Signaling, catalogue 
#4060, #4370, #9272, #9102), Actin (Sigma Aldrich, catalogue A2066), RETpY1062 (a 
gift from Dr. Brian Pierchala) were used at a 1:2,000 dilution, with secondary 1:10,000. 
Signals were developed using Western Lightning Plus ECL (PerkinElmer), films were 
scanned and quantified using ImageJ software. Controls for protein loading for each 
sample were standardized to total Akt, total Erk or Actin. 
 
Primary Cultures 
E18 primary cortical neurons from mouse were purchased frozen (BrainBits LLC). 
For biochemical assays, 0.25 x 106 cells were plated in 12-well plates coated with poly-
D-lysine, and cultured for 5 days in commercial neurobasal media (NbActiv1). Half of 
the media was exchanged every 2 days. Following the culture period, the media was 
removed and replaced with serum-free DMEM for a 3-hour starvation. Treatments were 
20 minutes, and lysates were prepared as described above. 
 
Cell Survival Assays 
Cell survival was measured by the MTT assay using optical density readings as the 
endpoint. 2000-5000 cells were plated in 96-well format in serum-free media (SFM) 
(HCell-100, Wisent) and vehicle or test agents at concentrations of 5 μM and 10 μM 
were added. The positive control growth factors (GF) were used at optimal 
concentrations (30 ng/ml GDNF for MG87 RET/GFRα1, 25 ng/ml FGF2 for MG87 RET, 
30 ng/ml NGF for MG87 TrkA). FGF2 was used for MG87 RET cells as they do not 
respond to GDNF in the absence of GFRα1. Assay time was typically 72 hr, at which 
point MTT reagent (Sigma Aldrich) was added. Assays were repeated at least 3 times. 
MTT optical density (OD) data were standardized to growth factor = 100%, and SFM = 
0%, using the formula [(ODtest – ODSFM)*100 / (ODGF – ODSFM)]. 
 
Compounds 
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Test compounds were acquired from the NCI/DTP repository (http://dtp.cancer.gov), 
through searches of the PubChem Compound database (Kim, Thiessen et al. 2016). 
Upon receipt, structures were coded for simplicity. The original identifiers and IUPAC 
names are: 4-amino-8-hydroxynaphthalene-2,6-disulfonic acid (NSC37051) compound 
7 (CAS 6271-90-5); 5-amino-4-hydroxynaphthalene-1,6-disulfonic acid (NSC37052) 
compound 8 (CAS 6271-89-2); (3Z)-6-amino-4-oxo-3-
(phenylhydrazinylidene)naphthalene-2,7-disulfonic acid (NSC45189) compound 9 
(CAS 6222-38-4); 5-amino-3-[[4-[4-[(4-amino-2-methylphenyl)diazenyl]phenyl] 
sulfanylphenyl]hydrazinylidene]-6-[(4-nitrophenyl)diazenyl]-4-oxonaphthalene-2,7-
disulfonic acid (NSC65571) compound 15 (CAS 6950-40-9); 4-amino-3-[(2,5-
dichlorophenyl)diazenyl]-5-oxo-6-[[4-[4-[2-(4-oxocyclohexa-2,5-dien-1-
ylidene)hydrazinyl]phenyl] sulfanylphenyl]hydrazinylidene]naphthalene-2,7-disulfonic 
acid (NSC75661) compound 23; (3E)-5-amino-3-[[4-[4-[(4-amino-6-sulfonaphthalen-1-
yl)diazenyl]phenyl] phenyl]hydrazinylidene]-6-[(4-nitrophenyl)diazenyl]-4-
oxonaphthalene-2,7-disulfonic acid (NSC77520) compound 24; 4-amino-3-[(4-
nitrophenyl)diazenyl]-5-oxo-6-[[4-[4-[2-(4-oxocyclohexa-2,5-dien-1-
ylidene)hydrazinyl]phenyl]sulfanylphenyl]hydrazinylidene] naphthalene-2,7-disulfonic 
acid (NSC79723) compound 28; (3Z)-5-amino-3-[[4-[4-[(2,4-diamino-5-
methylphenyl)diazenyl]phenyl]phenyl]hydrazinylidene]-6-[(2,5-dichlorophenyl)diazenyl]-
4-oxonaphthalene-2,7-disulfonic acid (NSC79730) compound 29; 4-amino-3-[[4-[4-[(1-
amino-5-sulfonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]-5-oxo-6-
(phenylhydrazinylidene)naphthalene-2,7-disulfonic acid (NSC79745) compound 35 
(CAS 6486-54-0); (3Z)-5-amino-3-[[4-[4-[(2,4-diamino-3-methyl-6-
sulfophenyl)diazenyl]phenyl] phenyl]hydrazinylidene]-6-[(3-nitrophenyl)diazenyl]-4-
oxonaphthalene-2,7-disulfonic acid (NSC80903) compound 36.  
SU5416 was purchased from Tocris (Cat. # 3037), and XIB4035 was purchased 
from Sigma (Cat. # SML1159). 
 
Synthesis and structural characterization of compounds 
See Supplemental information. Compound 8 was misannotated in the NCI library, 
and the correct structure is reported here. Other compounds were annotated correctly. 
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Animal models  
All animal procedures respected the IACUC guidelines for use of animals in 
research, and to protocols approved by McGill University Animal Welfare Committees. 
All animals were housed 12 hr dark-light cycle with food and water ad libitum. We used 
the “RHOP347S” transgenic mouse (expressing the human Rhodopsin mutated at 
amino acid position 347) in a C57BL/6J (B6) background (kindly donated by Dr. T. Li) 
(Li, Snyder et al. 1996). This model of RP faithfully replicates the features of disease 
progression in humans. Both male and female animals were used in the experiments.  
For retinal cultures, animals at post-natal day 18 weighing between 10-12 g were used.  
For intravitreal injections and histochemical studies, animals 8 weeks of age were used, 
weighing between 20-25 g. 
 
Retinal Organotypic Cultures 
Whole eyes were enucleated and whole retinas dissected from wild-type and 
RHOP347S mice at post-natal day 18 were used for organotypic culture experiments.  
Following enucleation, eyes were placed in a petri dish with PBS. The cornea was 
perforated and cut away along the ora serrata, leaving room to remove the lens.  Whole 
intact retinas were then freely dissected away from the sclera and immediately 
transferred into 24 well plates containing 500 μl of culture medium (DMEM/F12 
supplemented with 10 mM NaHCO3, 100 μg/ml Transferrin, 100 μM Putrescine, 20 nM 
Progesterone, 30 nM Na2SeO3, 0.05 mg/ml Gentamicin, 2 mM L-Glutamine, and 1 mM 
Sodium Pyruvate). Under sterile conditions, the media was gently removed and 
replaced with fresh media containing the treatments or controls, and incubated at 37°C 
and 5% CO2 for 24 hr. Compounds were tested at a concentration of 20 μM, GDNF at 
500 ng/ml. Cell grade DMSO was used for vehicle treatments and was 0.5% by volume. 
Retinas were then used for TUNEL staining.  
 
TUNEL staining 
Staining was performed using the DeadEnd Fluorometric TUNEL system (Promega). 
RHOP347S retinas in culture (n=4 for GDNF treatements, n=3 for test compounds) 
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were first fixed in 4% PFA in PBS and kept at 4°C overnight. Three quick washes in 
PBS-0.2% BSA were done the next day, followed by three 30-minute permeabilization 
steps using 2% Triton X-100 in PBS.  Retinas were then incubated with 20 μg/mL 
Proteinase K in PBS for 15 minutes, briefly re-fixed in 4% PFA in PBS for 30 minutes 
and washed again with PBS-0.2% BSA before being transferred into Eppendorf tubes. 
Samples were incubated with 50 μl of equilibration buffer for 20 minutes, then 25 μl of 
TdT reaction mixture for 2.5 hr at 37°C. The reaction was terminated using a 30 minute 
incubation of 2X SSC solution. The retinas were mounted with the ganglion-cell layer 
facing up using Vectashield with DAPI.. For image acquisition, the retinas were divided 
into 4 quadrants, and 3 pictures with a 20X objective were taken in each area (central, 
mid, peripheral) for a total of 12 images of the outer-nuclear layer (ONL) per retina. 
Total TUNEL-positive cells were counted in each image semi-automatically (ImageJ). 
Counts were verified by at least one other person blinded to the experimental 
conditions. Wild-type retinal flat mounts were used as negative controls. 
 
Immunohistochemistry 
After enucleation, the eyes were immersed overnight in fixative composed of 4% 
PFA in PBS at 4°C, followed by cryoprotection by soaking in 30% sucrose overnight at 
4°C. Eyes were frozen in O.C.T tissue TEK and cryostat sections were cut and mounted 
onto gelatin-coated glass slides. Sections (14 μm thick) were washed with PBSand then 
incubated in PBS containing 3% normal goat serum, 0.2% Triton X-100 and 3% bovine 
serum albumin (BSA) for 2 hr. After, sections were incubated overnight at 4°C with 
primary antibody (1:250 p-MAPK, Cell Signaling #4370; 1:250 p-Akt, Cell Signaling 
#4060; 1:400 CRALBP, Abcam ab183728). The sections were rinsed and incubated 
with secondary antibody for 1 hr at room temperature. Then, sections were washed and 
coverslipped using Vectashield mounting media with DAPI. 
 
Image acquisition (fluorescence microscopy) and data analysis 
Pictures were taken as Z-stacks of confocal optical sections using a Leica confocal 
microscope at a 20X objective. Images were equally adjusted using Adobe Photoshop 
CS 8.0 to remove background signals. 
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For each experimental condition, a minimum of 6 images were acquired from 3 
sections cut from different areas of the retina (n=3 retinas per group). The area of the 
profiles of the cells expressing pErk and pAkt was measured using ImageJ software. 
 
Intravitreal injections 
Mice were anesthetized with isoflurane, delivered through a gas anesthetic mask. 
The treatments were delivered using a Hamilton syringe. Injections were done using a 
surgical microscope to visualize the Hamilton entry into the vitreous chamber and 
confirm delivery of the injected solution. 3 μl of a 2 mM stock solution composed of 50% 
DMSO in PBS were delivered. After the injection, the syringe was left in place for 30 
seconds and slowly withdrawn from the eye to prevent reflux. Experimental right eyes 




The quantitative data were subjected to statistical analyses using GraphPad Prism 5 
software, and are presented as mean ± SD for all studies. The differences between 
groups were determined by ANOVA (multiple groups) followed by Dunnett’s or 
Bonferroni-corrected t-tests. Student t-tests were performed to compare two groups. p-
values below 0.05 were considered to indicate statistically significant differences 
between groups.  The number of experimental replicates was pre-determined based on 
the level of variation observed in previous work, and each experiment was reproduced 
the number of times indicated. The nature of the experiments are exploratory, and as 
such are not testing a pre-specified null hypothesis.  P-values are therefore meant to be 
descriptive in their interpretation. 
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Results 
In vitro screening:  Identification of selective RET agonists 
Initial hits emerged and were identified by a luciferase-reporter assay (Sidorova, 
Matlik et al. 2010) monitoring Erk activation in cells expressing GDNF receptors. 
Selected compounds (NCI/DTP chemical repository, and the PubChem database) (Kim, 
Thiessen et al. 2016) were screened at 5 and 20 μM concentrations (Supplemental 
Table 1). A small family of compounds that increased luciferase activity >1.5 times, 
consistently in more than three independent luciferase-reporter assays, were 
considered candidates for further study.  
Candidates, coded 15, 23, 24, 28, 29, 35, and 36, were tested in biochemical assays 
for stimulation of RET phosphorylation (pRET), and downstream phosphorylation of Akt 
(pAkt) and Erk (pErk) using transfected MG87 fibroblasts stably expressing either RET 
only or RET/GFRα1 (untransfected or TrkA-transfected MG87 cells were used as 
controls). Structures are shown in Supplemental Figure 1.  Cells were treated with 
compounds, DMSO vehicle (negative control), or GDNF (positive control), and lysates 
were analyzed by Western blot for pRET (specific antibody to RET-pY1062), pAkt and 
pErk.  
Compounds 15, 24, 28, 29, 35, and 36 were active and generated pAkt and pErk 
signals in MG87 RET/GFRα1 cells. The RET-pY1062 does not yield a quantifiable signal 
(Figure 1A), but pAkt and pErk quantifications are shown (Figure 1B). Biochemical 
activation by compounds was comparable to the optimal dose of GDNF. Compound 23 
was not active, though it is a structural analog of the active compounds. 
In MG87 RET cells compounds 15, 24, 28, 29, 35, and 36 also activate RET in the 
absence of GFRα1 (Figure 1C, quantified in Figure 1D); but, as GDNF requires the 
presence of GFRα1 receptor, GDNF was not active in these cells. Note that the 
compounds activate RET in the absence of GFRα1, but GFRα1 expression dampens 
RET activation by some compounds (especially at the lower concentrations of 5-10 μM). 
An example of dose-dependent activation of RET, Akt and Erk is shown for compound 
29 (Figure 1E).  
To evaluate RET selectivity and RET dependence, counter-screens were performed 
using the MG87 TrkA cell line expressing the TrkA receptor tyrosine kinase. In MG87 
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TrkA cells the positive control is Nerve Growth Factor (NGF), and vehicle and 
compound 23 were used as negative controls. Compound 35, an agonist of RET, did 
not activate any signals in MG87 TrkA cells. There were no increases in pErk, pAkt or 
pTrkA compared to negative control compound 23 or to vehicle (Figure 1F). In positive 
controls, NGF increased pTrkA, pAkt and pErk levels. Hence, compound 35 appears to 
be RET-selective or dependent on RET-expression. Compound 35 was selected for 
further studies. 
 
Optimization of selective RET agonists 
Analogs of compound 35 in the NCI database yield compounds 7, 8, and 9, also 
procured from the NCI (structures are listed in Supplemental Figure 1). In MG87 
RET/GFRα1 cells, compound 8 acted as a RET agonist and significantly increased pAkt 
and pErk, (Figure 2A, quantified in 2B). Compound 7 also appeared to exhibit some 
activity, with a biased trend for pErk. Compound 9 was inactive.  
In MG87 RET cells (lacking GFRα1) compound 8 activated RET and significantly 
increased the levels of RET downstream targets pAkt and pErk, and all other 
compounds and GDNF were inactive (Figure 2C, quantified in 2D).  While remaining 
non-significant, the same biased pErk signaling profile for compound 7 was observed in 
these cells as well. 
RET selectivity was tested in counter-screens using MG87 TrkA cells. Compounds 
7, 8, and 9 did not generate pAkt or pErk or pTrkA signals, while positive control Nerve 
Growth Factor (NGF) activated these signals (Figure 2E, quantified in 2F). These data 
indicate that compound 8 (like parental compound 35) remains RET-selective or RET-
dependent, and does not require co-expression of GFRα1, while compounds 7 and 9 
are negative controls.  
Signaling was further evaluated in E18 mouse primary cortical neurons which 
endogenously express RET and GFRα1, and respond to GDNF (Catapano, Arnold et al. 
2001, Bonafina, Fontanet et al. 2018). Increases in pAkt were detectable following 
treatment with GDNF (200 ng/ml) or compound 8 (10 and 20 μM) (Figure 2G). These 
data confirm RET activation by compound 8 in primary neurons.  
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Agonism by compound 8 requires the RET kinase to be active. In MG87 
RET/GFRα1 cells, the pAkt and pErk induced by GDNF or by compound 8 are 
completely ablated when cells are pre-treated with RET kinase inhibitor SU5416 
(Mologni, Sala et al. 2006) (Figure 2H).  
 
Compound 8 is a RET ligand 
We examined the kinetics and affinity of RET-compound 8 interactions using real-
time surface plasmon resonance (SPR). Recombinant human RET extracellular 
ectodomain was amine-coupled to SPR sensors, with reference sensor having no 
protein. A fixed concentration (100 μM) screening of compound 8 to RET-coated 
surfaces showed substantial binding with slow dissociation kinetics (Figure 3A). Under 
the same binding conditions and on the same chip, inactive compound 9 failed to 
interact with RET (Figure 3A).  
Dose-dependent titrations (Figure 3B) showed that on low-density RET surfaces 
compound 8 generated signals (e.g. 150 RU at 12.5 μM and 230 RU at 25 μM, see 
arrows). Complementary multi-cycle analyses indicated that compound 8 has sub-
micromolar affinity for RET (Figure 3C). After the binding studies using titrations of the 
compound, we verified that immobilized RET protein was still present on chip surfaces 
as it was bound by anti-RET monoclonal antibodies (mAb). The anti-RET mAb 
generated signals correlating binding to the low-density and the high-density RET-
loaded chip surfaces (Figure 3D). These data indicate that compound 8 is a genuine 
ligand of the RET ectodomain.   
 
Compound 8 induces signals through RET phosphorylation 
Taken together, the data strongly support RET as the main target for the panel of 
molecules tested. Moreover compound 8 binds to RET directly.  
Compound 8 and compound 9 (negative control) were selected for dose-dependent 
studies in MG87 RET/GFRα1 cells. From lysates prepared from treated or control cells, 
RET was immunoprecipitated, and total pTyr was quantified by western blotting. 
This technique allows the direct detection and quantification of pRET. The data show 
dose-dependent induction of pRET by compound 8, comparable to GDNF, while 
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compound 9 was inactive over the full concentration range (Figure 3E, quantified in 
3G). Similar experiments in MG87 RET cells showed that compound 8 induces 
detectable increases in pRET whether or not cells express GFRα1 (Figure 3F). 
These data demonstrate that RET is a pharmacological target for compound 8, and 
corroborate the biochemical findings that GFRα1 is not necessary for the compound to 
induce signaling. However, we note that the 50-100 μM concentrations that induce 
significant pRET levels are higher than the 5-20 μM concentrations that afford detection 
of pAkt and pErk. This can be explained by signal amplification, and by the transient 
nature of pRET which reportedly is difficult to detect because it is rapidly targeted for 
degradation (Pierchala, Milbrandt et al. 2006). Therefore, small, undetectable changes 
in phospho-RET may lead to much larger increases in the effectors pAkt and pErk.  
 
Small molecule RET activation does not require GFRα1 expression but is 
regulated by GFRα1 likely via an allosteric mechanism 
Given that compound 8 induces RET-pY1062, a phosphotyrosine linked to the survival 
promoting effect of GDNF in neurons (Runeberg-Roos and Saarma 2007, Ibanez 2013) 
we quantified in MTT assays the cell survival / active metabolism as a biological 
correlate of the biochemical data.  
MG87 RET, MG87 RET/GFRα1, and MG87 TrkA cells were treated with test 
compounds 7 and 8. Inactive compound 9 and vehicle were used as negative controls. 
As positive controls we used growth factors: FGF2 for MG87 RET (as these cells 
lacking GFRα1 do not respond to GDNF), GDNF for MG87 RET/GFRα1, and NGF for 
MG87 TrkA. The growth factors as positive controls were used at their optimal 
concentrations to afford maximal cell viability, which was set to 100%. Cells were 
cultured for 72 hr under serum-free conditions ± treatments.  
In MG87 RET cells compounds 7 and 8 (5-10 μM) supported viability to a significant 
~25% of control FGF2 (Figure 4A), and GDNF was inactive because these cells lack 
GFRα1. In MG87 RET/GFRα1 cells compounds 7 and 8 (5-10 μM) supported viability to 
~10% (non-significant) compared to control GDNF (Figure 4B). Control compound 9 
was inactive in all cell lines, as anticipated.  
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In MG87 RET/GFRα1 cells, at 10 μM compound 8 does not afford significant cell 
survival (Figure 4B), but signal transduction is significant (Figure 2). The discrepancy 
between biological (cell survival) and biochemical (pTyr) signals may be due to 
expression of GFRα1 negatively regulating ligand binding or long-term survival. A 
similar phenomenon was reported for GDNF mutants (Eketjall, Fainzilber et al. 1999). 
Hence, higher concentrations of compound 8 were evaluated in biological assays.  
In MG87 RET/GFRα1 cells compound 8 at 40 μM supported viability to a significant 
~65% of GDNF levels, while compound 9 remained inactive (Figure 4B). In counter-
assays using MG87 TrkA cells compounds 7 and 8 (as well as compound 9) were 
inactive at all concentrations, compared to positive control NGF (N) (Figure 4C).  
Overall, these biological data demonstrate that compound 8 binds RET, and acts as 
a selective RET agonist that –unlike GDNF– does not require GFRα1 co-receptors. 
Compound 8 via RET phosphorylation activates signal transduction pathways that 
afford neuronal survival independent of GFRα1 co-receptors. However, expression of 
GFRα1 co-receptors appear to modulate the long-term survival-promoting action of 
compound 8. The GFRα1 repression can be overcome with higher concentrations of 
compound 8, which achieve better cell survival.  
 
Pharmacological modulation of the regulation by GFRα1 
To interrogate how GFRα1 regulates compound 8-mediated activation of RET, we 
used XIB4035, an agent reported to modulate GFRα1 without having intrinsic signaling 
activity (Hedstrom, Murtie et al. 2014).  
In MG87 RET/GFRα1 cells, pre-treatment with 4 μM XIB4035 for 20 minutes 
completely blocked the biochemical signals activated by compound 8, without inhibiting 
GDNF signals. Cellular controls using MG87 TrkA cells showed that XIB4035 had no 
effect on either NGF or FGF2 growth factor signaling, demonstrating that the XIB4035 
block is selective (Figure 4D).  
Hence, expression of unbound GFRα1 negatively modulates the RET signals that 
are activated by compound 8, and this modulation can be overcome with higher 
concentrations of compound 8. Moreover, the GFRα1 bound by XIB4035 inhibits 
compound 8 activation of RET even more strongly. Given that compound 8 is a genuine 
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ligand of RET (see SPR studies, Fig. 3) we infer that the repression of compound 8 
activation of RET by unbound GFRα1 (and the even stronger inhibition by bound 
GFRα1•XIB4035) likely occurs through an allosteric mechanism.  
This concept would be useful for devising screening strategies. While the GFRα1 
ligand XIB4035 exacerbates RET inhibition, it is conceivable that there may be GFRα1 
ligands that reduce RET inhibition, and potentially could even allow ligand-independent 
activation of RET.  
 
Compound 8 reduces photoreceptor apoptosis in a retinitis pigmentosa 
model, and activates pErk and pAkt in vivo 
Compound 8 was tested for neuroprotective capabilities in the mutant RHOP347S 
transgenic mouse model of retinitis pigmentosa. This mutation of the rhodopsin gene 
causes a highly aggressive phenotype with ~50% photoreceptor death by post-natal day 
18, and nearly complete loss by post-natal day 28 (Li, Snyder et al. 1996).  
Organotypic cultures of RHOP347S retinas from post-natal day 18 mice cultured for 
24 hr exhibit TUNEL-positive staining in the photoreceptor layer (indicating apoptosis), 
with other retinal structures remaining free of apoptosis (Figure 5A). Controls using 
retinal explants from wild-type mice resulted in very low or absent TUNEL signal. 
Compound 8 (20 μM) affords a significant ~25% decrease in TUNEL-positive cells 
indicating neuroprotection in RHOP347S retinas. Representative pictures from the 
central retina (the region surrounding the optic nerve) demonstrate the reduction in 
TUNEL-positive cells (Figure 5A). In contrast, GDNF (500 ng/ml) did not reduce TUNEL 
counts compared to vehicle. These data indicate that compound 8 possesses disease-
modifying capabilities in the degenerating retina, with an efficacy that is above GDNF 
under the conditions evaluated. These data highlight the potential utility of using small, 
selective ligands over large proteins like GDNF as therapeutics. 
To further evaluate compound 8 in vivo, it was delivered by intravitreal injection in 
wild-type mice. In each mouse, one eye served as the test eye, and the contralateral 
eye received control vehicle. Retinal sections were prepared 1 hr later, and pErk and 
pAkt levels were analyzed by immunohistochemistry. 
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The effectors pAkt (Figure 5B) and pErk (Figure 5C) were increased after treatment 
with compound 8, mainly in Müller cells as confirmed by co-localization with the glial 
marker cellular retinaldehyde binding-protein (CRALBP). This is consistent with Müller 
cells expressing RET (Hauck, Kinkl et al. 2006, Del Rio, Irmler et al. 2011). High pErk 
and pAkt were noted particularly in the Müller glial cell processes and fibers projecting 
towards the photoreceptors. The retinal pErk and pAkt increases were a significant ~3-
fold and ~2-fold respectively compared to vehicle (quantified in Figure 5D). We were 
unable to localize pRET in these retinas, as the anti-pRET antibody does not label 
tissues, and activated pRET is rapidly targeted for degradation (Pierchala, Milbrandt et 
al. 2006). 
These data indicate that compound 8 is bioactive in vivo in the mouse retina, and the 
neuroprotective effect seen in the experiments above likely derives from Müller glia 
supporting the photoreceptor population in a paracrine manner. 
 
Compound 8 is incorrectly curated in the NCI library 
In an effort to develop structure-activity relationships, and to generate new chemical 
entities, we attempted synthesis of analogs of compound 8. Surprisingly, the in-house 
synthesized compound 8 and its derivatives were inactive. 
Thus, we analyzed in detail the identity of compound 8 procured from the NCI, 
though the amount of material provided was quite limiting. Reverse-phase HPLC 
analysis revealed that NCI compound 8 has a major peak with 90% of the material, and 
the remaining material was a mixture (Supplemental Figure 2). The major fraction was 
isolated and characterized.  
The mass of compound 8 (ESI Mass Spec) that we obtained matched that reported 
by the NCI, however the 1H-NMR spectra revealed an inconsistency with the proposed 
structure (Supplemental Figure 3). The triplet observed around 7.4ppm suggested an 
aromatic proton with two neighboring protons. This resonance is not possible given the 
side-group configuration of compound 8 reported in the NCI database. However, this 
resonance pattern and the mass are consistent with a positional isomer 4-Amino-5-
hydroxy-1,3-naphthalenedisulfonic acid.  
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We acquired 4-Amino-5-hydroxy-1,3-naphthalenedisulfonic acid commercially (TCI), 
and this isomer had a mass and 1H-NMR spectra matching that of compound 8. The 
two agents (NCI-compund 8 and 4-Amino-5-hydroxy-1,3-naphthalenedisulfonic acid) 
also co-eluted in Reverse-phase HPLC under different buffer conditions, confirming a 
likely incorrect structural assignment of compound 8 at the NCI database.   
Following these findings, we also examined mass spectra of other compounds 15, 
23, 29, and 35. The mass of all these agents are reported correctly in the NCI database. 
Moreover, 1H-NMR spectra of compounds 29 and 35 are consistent with the structures 
reported in the NCI database, and they are likely correct. While the binding and the 
bioactivity we report for compound 8 (and other compounds) are conclusive, these 
findings serve as a cautionary note when screening large chemical databases. Further 
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Discussion 
We have characterized a novel class of small molecules that can activate RET. The 
small molecules provide improved RET receptor specificity compared to GDNF which 
requires GFRα1 for activating RET (Sariola and Saarma 2003, Gash, Zhang et al. 2005, 
Touchard, Heiduschka et al. 2012), and binds to other targets such as heparan sulphate 
proteoglycans (Bespalov et al. 2011).  
RET-selective ligands were useful as a chemical biology tool to evaluate 
GFRα1•RET functional interactions. We show that expression of GFRα1 (in the 
unliganded state) dampens the trophic efficacy of compound 8, while in the bound state 
(with XIB4035) it further inhibits pAkt/pErk signals induced by compound 8. The data 
highlights the dynamic relationships that exist between RET and GFRα1 receptors.  
RET-selective ligands were useful also as neuroprotective agents, and compared to 
GDNF, are superior therapeutics ex vivo and in vivo, reducing neuronal death.  
 
RET–dependent signals and selectivity, possible mechanism of action, and the 
influence of GFRα1 
Compound 8 is a genuine ligand of RET ectodomain. Compound 8 and related small 
drug-like compounds activate the intracellular downstream effectors Akt and Erk. 
Distinct from GDNF, the compounds activate RET in cells lacking the GFRα1 co-
receptor. The agents do not affect GDNF functionally, do not require GDNF or GFRα1 
to produce biological effects, and appear to be RET-selective.  
There are other reported small molecule “GDNF mimetics” acting as RET agonists, 
(Saarma, Karelson et al. 2011, Bespalov, Sidorova et al. 2016, Sidorova, Bespalov et 
al. 2017, Ivanova, Tammiku-Taul et al. 2018). For example, BT13 is a selective RET 
agonist, however it suffers from low solubility and has poor pharmacological properties, 
as also do other reported agents. Moreover, BT13 and other agents reportedly compete 
with GDNF binding; hence if used as therapeutics they would reduce any benefit 
provided by endogenous GDNF. Another agent XIB4035 acts as a GFRα1 modulator, 
but it requires the presence of GDNF and acts only on cells co-expressing RET/GFRα1 
(Tokugawa, Yamamoto et al. 2003, Hedstrom, Murtie et al. 2014). 
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We speculate that the RET-activating agents we report here may be allosteric, 
though this notion remains unproven. Analysis of the RET/GFRα1 interface revealed a 
potential allosteric binding site for small molecules (Ivanova, Tammiku-Taul et al. 2018). 
An allosteric mechanism would be consistent with the ligand-independent regulation of 
GFRα1 upon RET (Treanor, Goodman et al. 1996), and observations that mutant forms 
of GDNF with low affinity for GFRα1 binding can signal through RET but require GFRα1 
to be present (Eketjall, Fainzilber et al. 1999).  
RET is a receptor tyrosine kinase (RTK), a family of receptors generally considered 
to require homodimerization and/or a conformational reorganization of homodimers for 
activation. It is unlikely that the small molecules would be capable of inducing RET 
dimerization given their small size and limited surfaces, and the fact that they are 
asymmetrical and most likely monovalent. However, all RTKs exist at equilibrium 
between monomeric and dimeric (or oligomeric) forms in the absence ligand, such that 
a small molecule could induce a conformational change within a preformed receptor 
complex. This ‘dynamic equilibrium’ phenomenon has been shown for other 
neurotrophin RTKs (Maliartchouk, Debeir et al. 2000, Maliartchouk, Feng et al. 2000, 
Mischel, Umbach et al. 2002), and was suggested for RET (Bespalov and Saarma 
2007).  
Compound 8 rescues MG87 RET cells from serum-deprivation induced death, but to 
rescue MG87 RET/GFRα1 cells it required relatively high concentrations, well beyond 
those needed for pAkt and pErk activation. While the small molecules activate signals in 
the absence of GFRα1, agonism leading to cell survival can be partially suppressed by 
the presence of GFRα1. The partial suppression of RET activation by GFRα1 can be 
overcome by increasing the concentration of compound 8, further suggesting an 
allosteric impact or an influence on ligand affinity. This is consistent with discrepancies 
between biochemical signals and biological outcomes reported for GDNF (Lindgren, 
Leak et al. 2008). GDNF-activated RET signaling can be progressively dampened by 
increasing expression levels of GFRα1 (Trupp, Raynoschek et al. 1998).  
Since GFRα1 also determines the cellular localization of activated RET to lipid rafts, 
which in turn can influence signaling, perhaps this is a mechanism for GFRα1 
suppression of RET activation by compound 8. The functional antagonism of compound 
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8 (a RET-activator) by XIB4035 (a reported GFRα1 ligand) further suggests a ligand-
dependent allosteric cross-regulation.  
Comparable to the functional cross-talk between GFRα1–RET described here, there 
are reported agonists of Trk receptors (Maliartchouk, Feng et al. 2000, Zaccaro, Lee et 
al. 2005, Massa, Yang et al. 2010) whose function can be regulated by p75NTR co-
receptors.  Regulation can be allosteric, with the ligands promoting Trk-p75 interactions, 
or with the ligands unmasking a cryptic receptor hot spot (Zaccaro, Ivanisevic et al. 
2001, Ivanisevic, Banerjee et al. 2003, Guillemard, Ivanisevic et al. 2010). 
 
Therapeutic utility 
GDNF plays an important neuroprotective role in the developing and the adult retina, 
supporting neuronal populations. Transgenic mice expressing human rhodopsin with a 
proline-serine substitution at residue 347 faithfully replicate the RP disease, and were 
chosen for our studies (Li, Snyder et al. 1996). Compound 8-induced RET signaling 
translated into a functional neuroprotective effect, with a significantly reduced number of 
TUNEL counts in the ONL, compared to vehicle. In contrast, GDNF itself failed to 
reduce TUNEL counts with concentrations up to 500 ng/ml (using recombinant GDNF 
produced in E. coli, or in mammalian CHO cells).  
The reason for the failure of GDNF in our therapeutic experiments is possibly due to 
the fact that we used a single dose, attempting to evaluate a translational paradigm. 
Other studies, including those of degeneration due to RP either employ multiple doses 
or achieve sustained GDNF expression and release (McGee Sanftner, Abel et al. 2001, 
Gregory-Evans, Chang et al. 2009, Ohnaka, Miki et al. 2012). GDNF can also fail due to 
clearance after binding to extracellular matrix and transmembrane heparin sulphate 
proteoglycans and other proteins upregulated in the degenerating retina (Landers, 
Rayborn et al. 1994). 
RP is one of the most common forms of inherited visual loss, affecting over a million 
people worldwide, and is the result of about 400 possible mutations in any one of 
multiple genes such as rhodopsin. The RP disease is characterized by progressive 
degeneration of photoreceptors initiated by the mutant rhodopsin, followed by retinal 
pigmented epithelium stress, and toxic/oxidative/pro-inflammatory damage to the visual 
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system and irreversible blindness (Guadagni, Novelli et al. 2015). There is no cure or 
effective treatment. Given that RP is the result of one of many possible mutations in any 
one of multiple genes, the availability of a small molecule neuroprotective agent would 
allow treatment of a broad spectrum of patients regardless of disease etiology. 
Intravitreal administration of compound 8 induced pErk and pAkt in Müller cells, 
consistent with other reports using GDNF and related growth factors (Wahlin, 
Campochiaro et al. 2000, Hauck, Kinkl et al. 2006). Our results support the notion of a 
non-cell autologous mechanism where neuroprotective signals likely originate from 
Müller glia acting in a paracrine fashion. This concept is consistent with the fact that 
ectopic expression of RET on photoreceptors failed to protect them from degeneration 
(Allocca, Di Vicino et al. 2007), and papers suggesting an indirect rescue of 
photoreceptors either through mitigation of toxic events within the retina, or by inducing 
paracrine release of trophic factors which then act on target neurons (Hauck, Kinkl et al. 
2006, Koeberle and Bahr 2008, Del Rio, Irmler et al. 2011).  
 
Chemical Database Screening: A cautionary tale 
Chemical libraries are a valuable resource for research initiatives. However, there 
continue to be complications. This is especially relevant given the rise of high-
throughput screening techniques, when often the data reported are not sufficient for 
others to interpret and/or replicate (Inglese, Shamu et al. 2007).  While some chemical 
repositories do explicitly state that they cannot assure the contents of their libraries, 
they are also not permitted to provide adequate details in the case of a discrepancy. 
This is the case for compound 8 and its derivatives where supplier information and 
storage conditions cannot be provided by the NCI (personal correspondence).  
The situation here is similar to the discovery of TIC10/ONC20, an anti-cancer 
therapeutic agent. TIC10/ONC201 emerged from a screen from the NCI library, and the 
structure had been only partially documented using mass spectroscopy (Allen, Krigsfeld 
et al. 2013). Inconsistencies led to the finding that the real active molecule was in fact 
an isomer of the structure reported by the NCI (Jacob, Lockner et al. 2014), and both 
the mixture as well as the correct compound were used for clinical development. In both 
TIC10/ONC201 and compound 8 the lack of a precise structure does not undermine the 
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biological data reported. However, considerable efforts must be directed at identifying 
the active component of compound 8 for future studies and reproducibility.  
Overall, our work demonstrates the concept that it is possible to develop small 
molecule RET agonists that do not require GFRα1, and which are devoid of many of the 
therapeutic hurdles of the GDNF protein. Using small molecules as probes, regulation of 
agonist-induced RET signals by GFRα1 is demonstrated. The data highlight the utility 
and advantages small molecules offer with respect to target validation and receptor 
biology. 
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Figure 1. Characterization of RET agonists.   
(A-B) Biochemical studies of RET activators in MG87 RET/GFRa1 cells.  Following 
serum deprivation, cells were treated with DMSO vehicle (V), 10 ng/ml GDNF (G), or 20 
μM compounds for 20 min.  Representative blot shown, cell lysates were probed for 
pRET-Y1062, pAkt, and pErk.  Total Akt and Erk used as loading controls. Increases in 
pRET-Y1062 were seen, however compounds generated large increases particularly in 
pAkt and pErk, with the exception of compound 23. (C-D) Biochemical studies of RET 
activators in MG87 RET cells, lacking GFRa1. Representative blot shown, 
demonstrating relevant signaling by this panel of compounds.  Note that GDNF is 
inactive in this cell type, and compound 23 remains inactive. (E) Western blots showing 
dose-dependent RET activation by compound 29 (2.5-20 μM) in both MG87 
RET/GFRa1 and MG87 RET cells, further suggesting GFRa1 independence. (F) 
Counter screens for selectivity in MG87 TrkA cells. Western blot quantification of NGF 
(N) at 30 ng/ml (positive control), or the selected compound 35 at 20 μM. Compound 23 
was used as a negative control. Compound 35 demonstrated the most favorable 
selectivity as it did not activate Akt or Erk in MG87 TrkA cells lacking RET. 
Western blot data were quantified from 3 independent experiments, expressed as mean 
± SD and standardized to Vehicle control. For pAkt *p<0.05, **p<0.005, ***p<0.0005. 
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Figure 2. Lead optimization.  
(A-B) Biochemical studies with compound 35 derivatives in MG87 RET/GFRa1 cells 
assayed 20 μM concentrations of compounds 7, 8, and 9 with a 20 min exposure time.  
Representative Western blot shown for RET-pY1062 and its effectors pAkt and pErk. 
GDNF (G) is GDNF positive control and vehicle (V) is the DMSO negative control.  
Compound 8 displayed a signaling profile which mirrored that of the parent compounds, 
while compound 7 generated a pErk biased signaling trend. Compound 9 was 
completely inactive. (C-D) Biochemical studies with compound 35 derivatives tested in 
MG87 RET cells.  Representative Western blot shown for RET-pY1062 and its effectors 
pAkt and pErk. GDNF (G) is GDNF positive control and vehicle (V) is the DMSO 
negative control. Signaling profiles of compounds 7,8, and 9 were similar to those 
observed in MG87 GFRa1/RET cells, indicative these derivatives maintained GFRa1 
independence. (E-F) Selectivity screens in MG87 TrkA cells, using 20 μM 
concentrations of compound 35 derivatives, stimulated for 20 min.  Representative blot 
for pTrkA and its effectors pAkt and pErk. NGF (N) is positive control and vehicle (V) is 
the negative control.  Compounds 7,8, and 9 were all inactive in these assays. (G) 
Compound 8 signaling in E18 mouse cortical neurons. Neurons were treated with 
compound 9 at 20 μM, GDNF at 100 and 200 ng/ml, and compound 8 at 10 μM and 20 
μM, for 20 min. Representative blot showing pAkt increases observed with both 
treatments of compound 8. Actin was used as loading control. (H) RET inhibition blocks 
compound 8 signaling. MG87 RET/GFRa1 cells were first treated with the RET 
antagonist SU5416 at 10 μM for 20 min, and then additionally for 20 min with GDNF (G) 
or compound 8. Vehicle (V) and SU5416 (S) alone are controls. SU5416 pre-treatment 
resulted in clear reductions in the signaling capacity of both GDNF and compound 8. 
Representative blot showing pAkt and pErk, with Actin as loading control. Vehicle (V) is 
the negative control. In panels B, D, and F, quantification of western blot data was 
standardized to total Erk or total Akt and expressed as mean ± SD from 3 independent 
experiments. For pAkt *p<0.05, **p<0.005, ***p<0.0005. For pErk #p<0.05, ##p<0.005, 
###p<0.0005 versus Vehicle, Dunnett’s test.  
 
 
This article has not been copyedited and formatted. The final version may differ from this version.














MOL # 118950 
 35 
Figure 3. Compound 8 is a RET ligand that induces RET tyrosine phosphorylation 
(A)  Surface Plasmon Resonance, real-time binding to recombinant human RET 
ectodomain. Representative, reference-subtracted SPR for sequential injections of 
buffer (PBS-T containing 2% (v/v) DMSO), compound 9 (100 μM, negative control), and 
compound 8 (100 μM) over amine-coupled high-density RET (4600 RU, solid black line) 
at 25 μL/min (60 sec association). (B)  Representative single-cycle SPR data for 
compound 8 (0 – 25 μM; 2-fold dilution series) injected over amine-coupled low-density 
RET (1650 RU, solid black line) at 25 μL/min (60 sec association +/- 60-600 sec 
dissociation).  Arrows indicate injection times. (C)  Representative multi-cycle SPR data 
for compound 8 (0 – 20 μM; 2-fold dilution series) injected over 1650 RU RET surface at 
25 μL/min (600 sec association + 900 sec dissociation); experimental titration series 
(grey lines) were fit globally to “1:1 kinetic” model in BIAevaluation software (black 
lines). (D)  Representative single-cycle SPR data for anti-RET monoclonal antibody (0 – 
210 nM; 2-fold dilution series) injected over 4600 RU RET (solid black line), and 1650 
RU RET (dashed black line) surfaces at 25 μL/min (60 sec association +/- 60-600 sec 
dissociation). (E-G) Compound 8 induces RET phosphorylation in a dose-dependent 
manner. MG87 RET/GFRa1 or MG87 RET cells were treated for 15 min with compound 
8, or control compound 9, at a concentration range of 5-100 μM, or controls GDNF (G) 
at 200 ng/ml, or vehicle (V). RET protein was immunoprecipitated and probed with 
4G10 mAb (detecting phosphotyrosine). Compound 9 was inactive at all concentrations, 
whereas compound 8 induced a marked increase in phosphorylated RET whether or not 
cells express GFRa1. In MG87 RET/GFRa1 cells compound 8 at 50 μM was as 
effective GDNF at 200 ng/ml. Quantification in panel G was standardized to total RET 
protein and expressed as mean ± SD from 3 independent experiments. **p<0.005, 
***p<0.0005 versus Vehicle, Dunnett’s test.  
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Figure 4. RET-mediated trophic signals activated by compound 8 are regulated by 
GFRa1. 
(A) Compound 35 derivatives mediate survival in MG87 RET cells.  Cells under serum 
starvation for 72 hr were treated with DMSO Vehicle (V), FGF (as these cells are 
insensitive to GDNF), or compounds 7, 8, and 9; at 5 and 10 μM concentrations. Cell 
survival/metabolism was assessed via the MTT assay. 10 μM concentrations of 
compound 7 or compound 8 yielded appreciable survival levels; whereas compound 9 
was inactive, as expected. (B) Compound 35 derivatives do not afford survival in MG87 
RET/GFRa1 cells under the same conditions.  In these cells, GDNF yielded significant 
survival while the trophic effects of compounds 7 and 8 diminished, suggesting a 
negative influence of the GFRa1 receptor. MG87 RET/GFRa1 survival increased with 
higher concentrations of compound 8, and reached significance at 40 μM, suggesting a 
negative regulatory role of GFRa1 expression on the functional outcome. (C) 
Compound 35 derivatives demonstrate selectivity as measured by cell survival.  MTT 
assays conducted in the MG87 TrkA cell line, covering the full concentration range of 5 
to 40 μM for each compound, were standardized to positive control NGF (N) and 
compared against Vehicle (V).  All compounds were completely inactive in this cell type, 
including GDNF (G). (D) Biochemical studies on the influence of GFRa1 and compound 
8.  MG87 RET/GFRa1 or MG87 TrkA cells were pretreated with 4 μM XIB4035 (a 
GFRa1 modulator) for 10 minutes before the addition of compound 8 at 10 μM, GDNF 
(G), NGF (N), or FGF2 (F). XIB4035 blocked the signaling of compound 8, but did not 
affect GDNF. Control experiments in the TrkA expressing cells showed that XIB4035 did 
not impact either NGF or FGF2 signals, overall supporting the negative regulatory role 
of GFRa1 specifically on compound 8 signaling. MTT Data are expressed as % survival 
relative to optimal growth factor ± SD from 6 independent experiments (each 
experiment n=4-8 replicate wells which were averaged). For each cell type, the 
respective trophic factor was standardized to 100%, and vehicle to 0%. * p <0.05, *** 
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Figure 5. Compound 8 is neuroprotective in the RHOP347S model of RP and 
activates Akt and Erk in retinal Müller Glial cells. 
(A) Compound 8 reduces neuronal death. Whole retinas of post-natal day 18 
RHOP347S mice were dissected for organotypic culture. Each paired set of retinas (left 
and right of the same mouse) were treated with either compound 8 at 20 μM or GDNF 
at 500 ng/ml in one retina, and DMSO vehicle (V) as control in the other retina. In a 
separate series of experiments, an inactive compound was also tested as control at 20 
μM.  Cultures were kept for 24 hr, then TUNEL staining was performed. Representative 
TUNEL images taken at 20x in the central retina are shown. Scale bar = 25 μm. 
Quantification of TUNEL-positive photoreceptors in the ONL shows that treatment with 8 
reduces apoptosis, while GDNF had no effect.  Data expressed as TUNEL-positive cells 
per mm2 ± SD, **p<0.005, Bonferroni-corrected t-test. (B-D) Compound 8 activates 
signals in vivo. Young adult mice (8 weeks old) were injected intravitreally (2 μg) with 
compound 8 in one eye or DMSO Vehicle in the contralateral eye.  Eyecups were 
collected after 1 hr and sectioned. Compound 8 increased pAkt in the inner nuclear 
layer, as well as in fibers projecting from cell bodies in the inner nuclear layer (Müller 
cell bodies). These signals co-localized with the Müller cell marker CRALBP. Compound 
8 also increased pErk in the inner nuclear layer, as well as in fibers projecting from cell 
bodies in the inner nuclear layer (Müller cell bodies) towards the ONL where the cell 
body of photoreceptors reside. These signals co-localized with the Müller cell marker 
CRALBP. Scale bar = 25 μm. RGC = retinal ganglion cell layer, INL= Inner nuclear 
layer, ONL = outer nuclear layer. Quantification of pAkt and pErk (n=3 per group) 
expressed as the fold-change in pixel area over vehicle ± SD, ***p<0.0005, Student t-
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Supplemental Data  
 
Small-molecule ligands that bind the RET receptor activate neuroprotective 
signals independent of but modulated by co-receptor GFRα1 
 
Sean Jmaeff, Yulia Sidorova, Hayley Lippiatt, Pablo F. Barcelona, Hinyu Nedev, Lucia 
M. Saragovi, Mark A. Hancock, Mart Saarma, H. Uri Saragovi 
 
  MG87 RET/GFRa1 MG87 RET 
Compound 5 μM 20 μM 5 μM 20 μM 
116 102.3124 134.8646 99.44444 117.8862 
206 162.1520 122.5338 121.6667 102.0325 
210 268.2869 265.0870 133.3333 121.1382 
302 121.7084 180.3675 102.7778 105.2846 
226 262.9070 227.1760 182.7778 163.4146 
224 131.9018 247.6306 99.44444 111.7886 
65 162.0104 230.2708 130.5556 174.3902 
47 136.6210 166.2476 140.0000 180.4878 
29 258.9429 330.0290 185.0000 252.0325 
 
Supplemental Table 1. Initial Compound Screening. In initial screens, ~200 
compounds were tested in MG87 cells with and without GFRα1 expression at 5 and 20 
μM.  Data from a select panel are shown as the average relative increase in 
luminescence versus vehicle from 4 experiments.  Compound 29 was selected as a 
candidate hit as it generated significant increases in both cell types, and subsequent 
analogues were then tested. In these assays, GDNF as positive control induces higher 
increases in luciferase activity, ranging from 60-80 fold over vehicle, consistent with 




Supplemental Figure 1.  




Structural Properties of NCI Database Compounds and 4-amino-5-hydroxynaphthalene-
1,3-disulfonic Acid  
4-amino-5-hydroxynaphthalene-1,3-disulfonic acid was obtained commercially from TCI 
America (Product Code: A0363) as a dark powder with reported purity of >85.0%.  Both 
Compound 8 and this product were purified on a 250 mm x 10 mm Kromasil 100-5-C18 
semi-preparative column.  A solvent gradient of 5-30%B was used for 30 minutes, 
where solvent A was HPLC grade H2O with 0.1% TFA, and solvent B was a 70/30 mix 
of Acetonitrile/H2O with 0.1% TFA. Samples of each were lyophilized yielding an off-
white powder and dissolved in D2O for subsequent 1H-NMR at 500 MHz. ESI mass 
spectra were obtained in negative mode with a Bruker Maxis Impact.  Compounds 15, 
23, 29, and 35 were dissolved in DMSO for mass spec analysis.  Sulfonic acids ionize 
preferentially in negative mode, and commonly yield di-charged ions by ESI (Holcapek 
1999). 
 
Supplemental Figure 2. HPLC chromatogram of the 5-30%B gradient showing 2 mg 
injections of 4-amino-5-hydroxynaphthalene-1,3-disulfonic Acid (Blue) and Compound 8 
(Black).  Both were relatively pure with the major fraction eluting ~3min. The overlay of 






Supplemental Figure 3.   
H-NMR resonances and the detected mass of 4-amino-5-hydroxynaphthalene-1,3-
disulfonic Acid and of Compound 8 show that they are likely the same molecule. 
Therefore compound 8 is incorrectly identified in the NCI database. Other agents 
(compounds 15,23,29,35) are also shown, and they correspond to the NCI-reports.  
Compound 8 (NSC37052). 1H-NMR (D2O, 500 MHz): δ 8.17 (s, 1H), 7.90 (dd, J = 8.6, 
0.9 Hz, 1H), 7.44 – 7.37 (t, 1H), 6.84 (dd, J = 7.8, 0.9 Hz, 1H). 
MS (ESI,-) m/z calcd for C10H7NO7S2 [M-2H]2- calcd: 158.4837, found: 158.4841 
4-amino-5-hydroxynaphthalene-1,3-disulfonic acid. 1H-NMR (D2O, 500 MHz): δ 
8.16 (s, 1H), 7.89 (dd, J = 8.5, 1.0 Hz, 1H), 7.44 – 7.37 (t, 1H), 6.84 (dd, J = 7.8, 1.1 Hz, 
1H). MS (ESI,-) m/z calcd for C10H7NO7S2 [M-2H]2- calcd: 158.4837, found: 158.4840 
Compound 15 (NSC65571). MS (ESI,-) m/z calcd for C35H25N9O9S3 [M-2H]2- calcd: 
405.5474, found: 405.5460 
Compound 23 (NSC75661). MS (ESI,-) m/z calcd for C34H21Cl2N7O8S3 [M-2H]2- calcd: 
410.5001, found: 410.5009  
Compound 29 (NSC79730). MS (ESI,-) m/z calcd for C35H25Cl2N9O7S2 [M-2H]2- calcd: 
408.5353, found: 408.5356  
Compound 35 (NSC79745). MS (ESI,-) m/z calcd for C38H25N8NaO10S3 [M-2H]2- calcd: 
436.0382, found: 436.0397 
 
 
 
 
 
